Indian NGO Challenges Patent For Roche’s Anti-HIV Valcyte
This article was originally published in PharmAsia News
An Indian group has filed a challenge to the government's grant of a patent for Roche's Valcyte (valglanciclovir) drug for treating HIV. Roche received the patent last year from the Chennai patent office, but the challenge by the Delhi Network of Positive People said it was granted without hearing opposing arguments by two non-governmental organizations. The contention of the opposition is that the drug is a known compound, or at least no more than a new version of a known substance, and therefore does not justify a patent. Roche also holds patents on the drug in other countries. (Click here for more
You may also be interested in...
MUMBAI - Multinational pharmaceutical companies eyeing the growing Indian market may find themselves confronting a challenging patent environment during the next few years as public interest groups look to further intensify patent oppositions
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Erectile problems prevent a quarter of Brits from being intimate with a partner. Viatris' Upjohn - which markets Viagra Connect in the UK - is working with the Men’s Health Forum, sexual health charity Brook and dating expert Sarah Louise Ryan raise awareness of the problem and get men talking about the issue with their partners and with healthcare professionals.